End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
13.46 CNY | -3.24% | -2.68% | -26.57% |
05-07 | US FDA Grants Clinical Trial Approval for Dongcheng Biochemicals' Injection | MT |
04-29 | Dongcheng Biochemicals' Unit Gets Nod to Trial Tumor Drug | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 37.05 times its estimated earnings per share for the ongoing year.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-26.57% | 1.54B | - | ||
+19.62% | 43.27B | B- | ||
+24.52% | 22.92B | B+ | ||
+20.29% | 15.43B | - | ||
+7.48% | 12.95B | B+ | ||
+42.51% | 11.83B | B | ||
-8.84% | 6.91B | B+ | ||
-0.05% | 6.79B | - | - | |
-8.87% | 5.73B | - | - | |
+13.13% | 5.55B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 002675 Stock
- Ratings Yantai Dongcheng Pharmaceutical Group Co.,Ltd.